Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Bevacizumab as an Adjunct to MMAE in Chronic Subdural Hematoma
NCT07729098Phase 1Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Jan 2029
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in chronic subdural hematoma (CSDH). Primary endpoints: Incidence of dose-limiting toxicities at 30 days and Incidence of Serious Adverse Events at 30 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT07729098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729098.